Table 2.
Strains of S. pneumoniae among adults aged 65 y and older.
| n (%)–[most prevalent serotype] |
||||||||
|---|---|---|---|---|---|---|---|---|
| Source | Country (year) | Study population (N) | PCV7a | PCV10-specific[1, 5, 7F] | PCV13-specific[3, 6A, 19A] | PPV23-specificb | PPV23 serotypes | NV serotypes |
| IPD in Europe | ||||||||
| Harboe et al. 201455 | Denmark (2011–13) | Adults with IPD aged ≥ 65 y (1439) | 97 (6.7)–[4] | 265 (18.4)–[1] | 224 (15.6)–[3] | 549 (38.2) | [NS] | 304 (21.1)–[NS] |
| Skoczynska et al. 20146 | Poland (2011–13) | Adults with IPD aged ≥ 65 y (373) | 116 (31.3)–[14] | 21 (5.7)–[1] | 110 (29.6)–[3] | 57 (15.3) | 9N: 3.8% • 22F: 3.0% • 11A: 2.1% 10A: 1.9% • 12F: 1.9% • 8:1.6% 15B/C: 1.1% | 67 (18.1)–[NS] |
| Guevara et al. 201456 | Spain (2010–13) | Adults with IPD aged ≥ 65 y (114) | 12 (10.5)–[NS] | 47 (41.2)–[NS]c | — | — | 55 (48.2)–[NS]c | |
| Verhaegen et al. 201457 | Belgium (2009–11) | Adults with IPD aged ≥ 65 y (742) | 59 (8.0)–[NS] | 146 (19.7)–[7F] | 210 (28.3)–[19A] | 214 (28.9) | 12F: 5.9% • 22F: 5.8% • 8: 3.8% | 141 (19.0)–[NS] |
| Other NS: 9.6% | ||||||||
| Navarro-Torne et al. 201518 | Europe (26 countries–2010) | Adults with IPD aged ≥ 65 y (1108) | 191 (17.2)–[NS] | 385 (34.7)–[NS]c | — | — | 532 (48.0)–[NS]d | |
| Ochoa-Gondar et al. 201558 | Spain (2006–09) | Adults with IPD aged ≥ 65 y (96) | 14 (14.6)–[14] | 17 (17.7)–[7F] | 29 (30.2)–[19A] | 13 (13.5) | 9N: 4.2% • 8; 12F: 2.1% • 10A; 15A; 17F; 22F; 33F: 1.0% | 38: 5.2% • 16/16F; 23B; 31: 3.1% |
| 11/11F; 23A; 24F: 2.1% | ||||||||
| 10B; 15A; 35F; 37: 1.0% | ||||||||
| IPD in Latin America | ||||||||
| Garcia Gabarrot et al. 20145 | Uruguay (2011–12) | Adults with IPD aged ≥ 60 y (150) | 14 (9.3)–[NS] | 52 (34.7)–[NS]c | — | 84 (56)d | [NS] | — |
| IPD in North America | ||||||||
| Moore et al. 201524 | US (2011–13) | IPD cases among adults aged ≥ 65 y (3618) | 45 (1.2)–[19F] | 95 (2.6)–[7F] | 423 (11.7)–[3] | – | 22F: 4.6% • 11A: 1.6%e | 6C: 2.7% • 23A: 2.0% |
| 35B: 1.8% •16F: 1.6%e | ||||||||
| Wortham et al. 201459 | US (2009) | Adults with IPD aged ≥ 65 y (1233) | 510 (41.4)–[NS]f | — | — | 723 (58.6)–[NS]f | ||
| non-IPD in Asia, North America, and Europe | ||||||||
| Kim et al. 201460 | South Korea (2013) | Adults with IPD or pneumococcal pneumonia aged ≥ 65 y (114) | 14 (12.3)–[19F] | 1 (0.9)–[7F] | 34 (29.8)–[3] | 32 (28.1) | 11A/D/F: 14.0% • 20; 22F: 3.5% | 34: 6.1% • 15A/F; 35B: 4.4% • 6D; 13: 2.6% • 6C; 7B/7C; 11E; 16F; 23A; 23B: 0.9% • Other NS: 3.5% |
| 15B: 2.6% • 10A; 33F: 1.8% • 8: 0.9% | ||||||||
| Richter et al. 201461 | US (2012–13) | Adults with IPD or non-IPD aged ≥ 65 y (346) | — | — | ≥ 73 (21.1)–[3]f | — | 11A; 22F: 6.0%g | 6C: 6.0% • 15A; 23A: 5.0%f |
| Domenech et al. 201462 | Spain (2009–12) | SP strains causing acute exacerbations among COPD patients aged 70.2 ± 8.7 y (197) | 23 (11.7)–[19F] | 5 (2.5)–[7F] | 30 (15.2)–[3] | 48 (24.2) | 11A: 6.1% • 10A: 4.0% | 15A: 9.6% • 6C: 5.6% |
| 17F; 22F; 33F: 3.0% | 23A; 23B: 4.5% | |||||||
| 9N; 12F: 1.5% • 15B: 1.0% | 16F; 35B: 3.5% • 31; 24F: 2.5% | |||||||
| 21; NT: 2.0% • 35F: 1.5% | ||||||||
| 34; 20; 15C: 1.0% | ||||||||
| 37; 10F; 13F; 35C: 0.5% | ||||||||
COPD: chronic obstructive pulmonary disease; IPD: invasive pneumococcal disease; NA: not applicable; NPC: nasopharyngeal carriage; NS: not specified; NV: non-vaccine; SP: S. pneumoniae
a
PCV7 serotypes: 4, 6B, 9V, 14, 18C, 19F, 23F;
b
PPV23-specific serotypes: 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, 33F;
c
PCV13 serotypes not found in PCV7;
d
non-PCV13 serotypes;
e
PCV13-serotypes and the 5 most common among non-PCV serotypes reported;
f
PCV13-serotypes;
g
serotype-specific data for the 8 most common serotypes by age group were reported.